A Phase 4 interventional study of Nifedipine (Adalat, BAYA1040) and Valsartan and Nifedipine (Adalat, BAYA1040) in Hypertension, sponsored by Bayer. Completed at 15 sites in Korea, Republic of. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2014-01-27.
Sponsored by Bayer · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing nifedipine in Hypertension — 3 open to participants now, 3 under way, 1 of them phase 3. Nifedipine · Hypertension.
Among the 29 studies testing nifedipine in Hypertension, this one is the 5th largest by enrollment, is one of 3 that started in 2010, is one of 12 in phase 4, and was the 8th registered.
6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.
Browse Hypertension studies →3 of the 29 studies testing nifedipine in Hypertension are open now, in 1 country. Recruiting first, the newest first:
The Cleveland Clinic · Sites in United States
Ages 18+ · Women only
Loma Linda University · Sites in United States
Ages 18+ · Women only
Nebraska Methodist Health System · Sites in United States
Ages 19+ · Women only
By country, each count listing its studies:
Nifedipine: first FDA approval 1981 (PROCARDIA). What it is approved for, and how studies give it, is on its page →
Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 20 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 9 · Phase 4 12
First in 2003; this study’s year is marked. 3 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 365 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 72 across the 29 interventional studies. Of the 20 that completed or were terminated, 4 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 29 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
33 studies in Hypertension by Bayer: none open now, none under way, none of them phase 3. Of 31 finished, 4 (13%) have results posted.
Among the 33 studies in Hypertension by Bayer, this one is the 7th largest by enrollment of the 20 interventional ones that give a count, is one of 6 that started in 2010, is one of 6 in phase 4, and was the 15th registered.
Bayer’s Hypertension studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 29 studies testing nifedipine in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bayer’s 33 in Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To determine whether the combination of nifedipine GITS and valsartan is more effective in reducing central blood pressure than nifedipine GITS or valsartan alone, and to determine whether nifedipine GITS is comparable to valsartan
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Nifedipine (Adalat, BAYA1040) and Valsartan
Drug: Nifedipine (Adalat, BAYA1040)
Drug: Valsartan
Drug pages: Nifedipine · Valsartan
Combination treatment with nifedipine GITS 30mg and valsartan 80mg, Once daily
Nifedipine 60mg, Once daily
Valsartan 160mg, Once daily
Central systolic blood pressure
Time frame: Week 8
Change in central diastolic blood pressure and pulse pressure
Time frame: Week 4,8
Change in central systolic blood pressure
Time frame: Week 4
Change in brachial systolic blood pressure and diastolic blood pressure
Time frame: Week 4,8
Change in brachial pulse pressure
Time frame: Week4,8
Change in augmentation index and augmentation pressure
Time frame: Week 4,8
Response rate(≥10 mmHg decrease of brachial SBP and ≥5mmHg decrease of brachial DBP)
Time frame: Week 4,8
Control rate (≤140/90 mmHg, 130/80 mmHg for diabetes, of brachial BP
Time frame: Week 4,8
The record gives a start of Jan 2010, a primary completion of Feb 2012 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Nifedipine · Valsartan